Please assess the completion status of the following clinical trial:

Trial Title: EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Gender: men and women~2. Ethnicity: all ethnic groups~3. Age: ≥18, \< 75 years~4. Diagnosis of T2D -A1C within the last 90 days must be \>7.5%~5. Obesity, BMI ≥30~6. An Employee, or the significant other of an employee, that is covered by the Cleveland Clinic Employee Health Plan~Exclusion Criteria:~1. Type 1 diabetes or known latent autoimmune diabetes of adulthood (LADA)~2. Glomerular Filtration Rate \<30 mL/min/1.73 m2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration Equation, CKD-EPI)~3. Current glucocorticoid therapy~4. Currently or within the past 3 months receiving an anti-obesity medication, or any other medication used for the primary intent of weight loss~5. Any condition, unwillingness or inability, not covered by any of the other exclusion criteria, which, in the study clinician's opinion, might jeopardize the subject's safety or compliance with the protocol~6. Mental incapacity or language barrier~7. Pregnancy or plans to become pregnant within the next 2 years~8. Personal or family history of medullary thyroid carcinoma~9. Personal or family history of Multiple Endocrine Neoplasia syndrome type 2~10. History of acute pancreatitis, severe liver disease (Cirrhosis), or severe disease of digestive tract~11. History of congestive heart failure~12. History of bariatric or metabolic surgery/procedure~13. Visit with an endocrinologist within the past 1 year~14. Prior participation in the Endocrinology and Metabolism Institutes Integrated Weight Management Program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Obesity-centric approach + AOM (Type: EXPERIMENTAL): Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately two years. After discussing with the study doctor, participants will receive one of the following listed 4 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) phentermine/topiramate extended-release, 3) naltrexone/bupropion extended-release and 4) liraglutide 3.0 mg
- Obesity-centric approach without AOM (Type: EXPERIMENTAL): Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately two years.
- Usual care approach (Comorbidity-centric approach) (Type: ACTIVE_COMPARATOR): Participants will receive the traditional usual care/standard of care approach to T2D, hypertension, hypercholesterolemia management for approximately two years.

Based on this trial design, predict the completion outcome and termination type (if applicable).